Amprion has licensed its seed amplification assay methodology to MLM Medical Labs, enabling α-synuclein testing across European clinical trial sites. This expands access to cerebrospinal fluid biomarker detection for neurodegenerative disease research, establishing a scalable pathway for identifying misfolded protein aggregates linked to Parkinson's disease and synucleinopathies.
Key Points
- SAAmplify-αSYN detects misfolded α-synuclein in cerebrospinal fluid samples
- Licensing agreement enables distributed testing across European research sites
- Dedicated protein manufacturing supports assay reproducibility and scalability
Longevity Analysis
Early detection of pathological protein aggregation represents a fundamental shift in neurodegenerative disease management. Misfolded α-synuclein precedes symptomatic neurodegeneration by years, making biomarker validation critical for identifying at-risk populations before cognitive or motor decline. Expanding access to this assay across research networks accelerates the ability to decode whether interventions—lifestyle, pharmacological, or behavioral—actually prevent or slow protein pathology progression. This infrastructure supports the transition from symptom management to early intervention, where the window for meaningful protection remains open.
Original published by LT Wire.